TABLE 1.
Design of study to elucidate the effects of pDNA vaccine design and in vivo EP on the resulting vaccine-specific immune response in rhesus macaques
| Group (n) | Macaque no. | Vector dose (mg) | Vector [encoded antigen(s)]a |
|---|---|---|---|
| 2d (6) | A1N093 | ||
| A1N098 | |||
| A1N111 | 4.25 | WLV-151 (HCMV-Gag/Pol) | |
| A2N040 | 4.25 | WLV-159 (SCMV-Env and HCMV-NTV) | |
| A2N043 | 1.5 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| A2N065 | |||
| 3a (6) | A1N020 | ||
| A1N104 | |||
| A2N009 | 2.8 | WLV-151 (HCMV-Gag/Pol) | |
| A2N024 | 2.8 | WLV-106 (HCMV-Env) | |
| A2N027 | 2.8 | WLV-147 (HCMV-NTV) | |
| A2N028 | 1.5 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| 3c (6) | A1N089 | ||
| A1N097 | |||
| A2N029 | 2.8 | WLV-159 (SCMV-Env and HCMV-NTV) | |
| A2N042 | 2.8 | WLV-008 (HCMV-Gag) | |
| A2N060 | 2.8 | WLV-146 (HCMV-Pol) | |
| A2N070 | 1.5 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| 3cE (6) | A1N078 | ||
| A1N086 | 0.56 | WLV-159 (SCMV-Env and HCMV-NTV) | |
| A2N010 | 0.56 | WLV-008 (HCMV-Gag) | |
| A2N014 | 0.56 | WLV-146 (HCMV-Pol) | |
| A2N036 | 0.30 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| A2N054 | |||
| 4a (6) | A2N092 | ||
| A2N053 | 2.13 | WLV-008 (HCMV-Gag) | |
| A2N077 | 2.13 | WLV-106 (HCMV-Env) | |
| A2N093 | 2.13 | WLV-146 (HCMV-Pol) | |
| A2N088 | 2.13 | WLV-147 (HCMV-NTV) | |
| A2N094 | 1.5 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| Control (6) | A1N040 | ||
| A1N080 | |||
| A1N112 | 8.5 | WLV-001a (empty vector control) | |
| A1N118 | 1.5 | WLV-104 (HCMV-IL-12 p35 and SCMV-IL-12 p40) | |
| A2N037 | |||
| A2N049 |
a
HCMV, human cytomegalovirus immediate-early promoter; Gag/Pol, made by fusion of the HIV-1 HXB2 gag-pol genes. SCMV, simian cytomegalovirus immediate-early promoter; Env, HIV-16101 Env gp160; NTV, made by fusion of the HIV-1 NL4-3 nef, tat, and vif genes.